Exscientia -Precision Design Service
- Working with sparse data allows us to design first in class molecules for the latest high-interest targets
- Generative Design and Active Learning, deliver unprecedented efficiencies to candidate discovery
- Balanced molecules encode efficacy, safety and bioavailabilty and maximise the chance of success in a clinical setting
For each project we collect all relevant experimental information irrespective of data type.
This can cover target-driven pharmacology, ADME, 3D structure, high content data and phenotypic readouts.
All these different sources of data can be used to build a coherent set of machine learning models for AI-design. This approach is highly advantageous and we refer to it as a data agnostic approach.
Our systems transform drug discovery into effective formalised design moves.
We were the first to demonstrate that AI algorithms can outperform human experts when given the same drug discovery optimisation challenge. We formalise each drug discovery project as a learning challenge, where each project has a distinct set of issues to be solved.
The faster the systems learn, the more efficiently compounds with a profile suitable for clinical assessment are identified. This benefits the human researchers freeing their time to work on other strategic aspects of each project
Our systems design molecules that simultaneously address multiple clinical requirements.
Through a combination of AI design, predictive models and experiment, our systems quickly explore and learn which areas of chemistry are most likely to balance the complex requirements for each drug discovery project.
Once promising areas are identified, the systems focus on designs that exploit those areas in order to identify the best compounds.
This balance of early exploration followed by exploitation enables rapid learning and delivers unparalleled progress from initial hits to clinical candidate.